Fidia boosts capital as GGHL converts bonds and receives new warrants

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialFidia Spa ( (IT:FDA) ) just unveiled an announcement. Fidia S.p.A. has issued and placed with Global Growth Holding Limited the second tranche of its 2026 convertible bond loan with warrants, comprising 25 bonds with a nominal value of €250,000 and 2.5 million attached warrants exercisable into shares at €0.10. The warrants, which are not listed and have a 60‑month duration, bring total outstanding POC-related warrants to 5 million, reinforcing a structured financing route designed to support the group’s capital needs. On the same date, GGHL requested and obtained conversion of 15 of these bonds at €0.09 per share, resulting in the issuance of 1,666,666 new Fidia shares directly admitted to trading, and lifting the subscribed capital increase for the POC to €400,000. Following this partial conversion, Fidia’s share capital rises by €150,000 to €10,247,761.90, with the total number of shares increasing to 34,631,817, signalling ongoing balance-sheet strengthening and a deeper equity stake for its financial partner. The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.11 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page. More about Fidia Spa Fidia S.p.A., based in Turin and listed on Euronext Milan, is a leading global provider of numerical control technology and high-performance integrated milling systems. With more than 40 years of experience and around 135 employees, it focuses on advanced solutions for the automotive mould sector and the aerospace industry, offering numerical controls, high-speed milling machines and CAM software for complex shapes. Average Trading Volume: 956,877 Technical Sentiment Signal: Strong Sell Current Market Cap: €3.3M Find detailed analytics on FDA stock on TipRanks’ Stock Analysis page.